News

OKYO Pharma Enters New Agreement with Tufts Medical Center

1 Mins read

The latest development from OKYO Pharma has sent the company’s share prices soaring by 19% to $2.23. In an exciting move, they have entered into a new agreement with Tufts Medical Center.

Clinical Trial for Neuropathic Corneal Pain

The agreement outlines plans for a 40-patient open-label clinical trial that will focus on evaluating the efficacy and safety of OK-101 in patients suffering from neuropathic corneal pain. This trial aims to provide valuable insights into the potential benefits of OK-101 for patients in a real-world clinical setting.

Milestones and Timelines

OKYO Pharma intends to file an Investigational New Drug application for neuropathic corneal pain in the fourth quarter of 2023. Once the application is allowed by the U.S. Food and Drug Administration, study enrollment will promptly commence. The trial is expected to be completed within six to nine months.

Budgetary Impact

Despite the significance of this trial, it is expected to have a minor budgetary impact. The total cost, including drug manufacture and formulation expenses for investigational use, is projected to be less than $1 million.

This collaboration between OKYO Pharma and Tufts Medical Center represents a significant milestone in advancing research and innovation in the field of neuropathic corneal pain treatment.

Related posts
News

Coinbase Unveils 'Everything Exchange' Bringing Tokenized Stocks to US Users

1 Mins read
Coinbase said it will begin offering tokenized stocks, derivatives, prediction markets and early-stage token sales to U Coinbase said it will begin…
News

High Risk 100 USD SAR Expert Advisor Settings

1 Mins read
DISCLAIMER: Forex trading has a risk of losing all your money. Martingale and hedging systems that we have used now are kind…
News

Trading ideas: FGV, Paramount ,Zetrix, United Malacaa, Jati Tinggit, Focus Point, Camaroe, Bursa, IGBREIT, Chin Teck, Dufu, DXN, Tasco

1 Mins read
KUALA LUMPUR: Here is a recap of the announcements that made headlines in Corporate Malaysia. Trading in FGV Holdings Bhd will be…

Leave a Reply

Your email address will not be published. Required fields are marked *